Makers Laboratories Ltd

Makers Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a reassessment across key parameters including valuation, financial trends, quality, and technical indicators. Despite some positive quarterly results, concerns over long-term profitability and valuation metrics have prompted this change, signalling caution for investors in the pharmaceuticals sector.

Makers Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid a challenging Pharmaceuticals & Biotechnology sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios adjusting relative to historical averages and peer benchmarks.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile and positive financial trends. The micro-cap pharmaceutical company’s recent performance and comparative metrics have prompted a reassessment of its quality, valuation, financial trend, and technical outlook, culminating in a more favourable stance by analysts.

Makers Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of late June 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, set against a backdrop of sector-wide valuation trends and company-specific performance metrics.

Makers Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 29 June 2026. The revision reflects a reassessment across four critical parameters: quality, valuation, financial trend, and technicals, with valuation concerns playing a pivotal role in the downgrade despite some positive quarterly performance.

Makers Laboratories Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions amid a competitive pharmaceutical sector. This article analyses the recent changes in key valuation metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s current price attractiveness.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 22 June 2026, driven primarily by an improved valuation grade and positive financial trends. Despite a recent dip in share price, the pharmaceutical micro-cap’s fundamentals and technical outlook have prompted a reassessment, signalling cautious optimism among analysts.

Makers Laboratories Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent dip in share price and ongoing sector headwinds. This change reflects evolving investor sentiment and improved relative valuation metrics compared to peers in the Pharmaceuticals & Biotechnology sector.

Makers Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This recalibration in price-to-earnings and price-to-book value metrics, when analysed against historical trends and peer comparisons, suggests a nuanced investment landscape for this micro-cap pharmaceutical player.

Makers Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a shift in technical indicators and a reassessment of valuation metrics. Despite some positive financial results in the recent quarter, the company’s long-term fundamentals and profitability trends have raised concerns, prompting a comprehensive review across quality, valuation, financial trend, and technical parameters.

Makers Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to a fair valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, highlights a renewed price attractiveness for investors within the Pharmaceuticals & Biotechnology sector. A detailed analysis of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios against historical and peer benchmarks reveals the evolving investment narrative for this micro-cap stock.

Makers Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer with a market capitalisation of ₹99.00 crores, reported consolidated net profit of ₹1.09 crores for Q4 FY26, marking a dramatic recovery from the previous quarter's ₹0.94 crores but raising questions about sustainability. The stock surged 2.63% to ₹165.55 in Monday's trading session, reflecting investor optimism despite persistent structural challenges that have plagued the company's long-term performance.

With a decisive surge to Rs 174 on 20 May 2026, Makers Laboratories Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This advance comes amid a backdrop of mixed market conditions, underscoring the stock’s relative strength and technical resilience.

Makers Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.